Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2025)

Historic Operating Leases for Agios Pharmaceuticals (AGIO) over the last 7 years, with Q4 2025 value amounting to $40.2 million.

  • Agios Pharmaceuticals' Operating Leases changed 0.0% to $40.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $40.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $40.2 million for FY2025, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' Operating Leases is $40.2 million, which was down 0.0% from $44.5 million recorded in Q3 2025.
  • Agios Pharmaceuticals' Operating Leases' 5-year high stood at $103.0 million during Q1 2021, with a 5-year trough of $40.2 million in Q4 2024.
  • Moreover, its 5-year median value for Operating Leases was $73.7 million (2022), whereas its average is $72.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 2944.66% in 2024, then changed by 0.0% in 2025.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Operating Leases stood at $85.7 million in 2021, then fell by 15.95% to $72.0 million in 2022, then dropped by 20.85% to $57.0 million in 2023, then fell by 29.45% to $40.2 million in 2024, then changed by 0.0% to $40.2 million in 2025.
  • Its Operating Leases stands at $40.2 million for Q4 2025, versus $44.5 million for Q3 2025 and $48.8 million for Q2 2025.